Pembrolizumab Nets 2 More Approvals

20/06/2019 15 min
Pembrolizumab Nets 2 More Approvals

Listen "Pembrolizumab Nets 2 More Approvals"

Episode Synopsis

Discussing recent FDA-approvals of pembrolizumab for metastatic or unresectable, recurrent Head & Neck Cancer (1st line) and Small Cell Lung Cancer (3rd line)